

Marc F Botteman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8525883/publications.pdf>

Version: 2024-02-01

40
papers

1,530
citations

471061

17
h-index

301761

39
g-index

40
all docs

40
docs citations

40
times ranked

2082
citing authors

#	ARTICLE	IF	CITATIONS
1	Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model. <i>Journal of Medical Economics</i> , 2021, 24, 410-420.	1.0	14
2	Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 458-468.	1.0	23
3	Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. <i>Supportive Care in Cancer</i> , 2020, 28, 857-866.	1.0	10
4	A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma. <i>Ophthalmology Glaucoma</i> , 2020, 3, 103-113.	0.9	19
5	Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. <i>Journal of Medical Economics</i> , 2020, 23, 330-346.	1.0	21
6	Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment. <i>Cancer Medicine</i> , 2020, 9, 6586-6596.	1.3	18
7	Medical oncology referral and systemic therapy of patients with advanced stage urothelial carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 945-957.	0.6	1
8	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 356-365.e1.	0.9	11
9	Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan. <i>Future Oncology</i> , 2019, 15, 4069-4081.	1.1	8
10	Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. <i>Journal of Medical Economics</i> , 2019, 22, 840-847.	1.0	6
11	Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. <i>Journal of Medical Economics</i> , 2019, 22, 662-670.	1.0	28
12	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , 2019, 28, 109-119.	1.5	14
13	Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16610-e16610.	0.8	2
14	Patient and caregiver benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 196-196.	0.8	3
15	Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches. <i>Neurology and Therapy</i> , 2018, 7, 141-154.	1.4	4
16	Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 245-253.	0.7	20
17	Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. <i>Muscle and Nerve</i> , 2018, 57, 829-837.	1.0	121
18	Performance status dynamics during treatment with gemcitabine plus paclitaxel versus gemcitabine alone for metastatic pancreatic cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1389-1396.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. <i>British Journal of Cancer</i> , 2017, 116, 1247-1253.	2.9	25
20	Economic Burden of Atopic Dermatitis in High-Risk Infants Receiving Cow's Milk or Partially Hydrolyzed 100% Whey-Based Formula. <i>Journal of Pediatrics</i> , 2015, 166, 1145-1151.e3.	0.9	10
21	Quality-adjusted survival with combination nab-paclitaxel+gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. <i>Journal of Medical Economics</i> , 2014, 17, 338-346.	1.0	22
22	Patterns of Clinical Management of Atopic Dermatitis in Infants and Toddlers: A Survey of Three Physician Specialties in the United States. <i>Journal of Pediatrics</i> , 2013, 163, 1747-1753.	0.9	37
23	Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 483-496.	0.7	12
24	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2013, 16, 19-29.	1.0	38
25	Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 425-437.	0.7	17
26	Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours. <i>Pharmacoeconomics</i> , 2012, 30, 373-386.	1.7	6
27	Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer. <i>Clinical Therapeutics</i> , 2012, 34, 1334-1349.	1.1	27
28	Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. <i>Clinical Therapeutics</i> , 2011, 33, 291-304.e8.	1.1	16
29	Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. <i>European Journal of Health Economics</i> , 2011, 12, 575-588.	1.4	15
30	Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 119.	1.0	16
31	Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. <i>Journal of Mental Health Policy and Economics</i> , 2010, 13, 27-35.	0.6	9
32	Health economics of insomnia therapy: Implications for policy. <i>Sleep Medicine</i> , 2009, 10, S22-S25.	0.8	28
33	Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. <i>Vaccine</i> , 2009, 27, 4694-4703.	1.7	18
34	Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. <i>Current Medical Research and Opinion</i> , 2008, 24, 753-768.	0.9	35
35	Economic impacts attributable to the early clinical benefit of atorvastatin therapy â€” a US managed care perspective. <i>Current Medical Research and Opinion</i> , 2007, 23, 1517-1529.	0.9	13
36	Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1127-1136.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Cost Effectiveness of Long-Term Treatment with Eszopiclone for Primary Insomnia in Adults. CNS Drugs, 2007, 21, 319-334.	2.7	37
38	Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Current Medical Research and Opinion, 2006, 22, 23-31.	0.9	32
39	Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Annals of Oncology, 2006, 17, 1072-1082.	0.6	54
40	The health economics of bladder cancer. Pharmacoeconomics, 2003, 21, 1315-1330.	1.7	725